EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial

Kelli M Richardson iD, Susan M Schembre, Michelle R Jospe, Annaliese Widmer, Heidi J Silver iD

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3725-3735

DOI: 10.1111/dom.16395 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.04.2025. Verfasst von Kelli M Richardson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Hauptthemen laut MEDLINE: Liraglutide, Prediabetic State, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, American Heart Association, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate changes in dietary intake following liraglutide treatment, compared to dietitian‐supported caloric restriction and a weight‐neutral control, and to assess dietary intake against nutrition recommendations. Materials and Methods Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian‐supported caloric restriction (−390 kcals/day) or dipeptidyl peptidase‐4 inhibitor (100 mg/day) for 14 weeks. Dietary intake was assessed via a single 24‐h dietary recall pre‐ and postintervention. Within‐group changes and between‐group differences in macronutrient and micronutrient intake, diet quality and food sources were evaluated, and the proportion of participants meeting nutrition recommendations was calculated.

Results

Seventy participants (69% female, 83% white) were included. Average age was 49.4 ± 11.3 years, and mean BMI was 39.5 ± 6.1 kg/m 2 . Significant differences in change in percent calories from protein ( p = 0.037), carbohydrates ( p = 0.019) and added sugar ( p = 0.002) were observed across groups, with those in the caloric restriction group having the greatest increase in protein and decreases in carbohydrates and added sugar. Micronutrient intake did not significantly differ between groups nor did Total Healthy Eating Index (HEI)‐2020 scores. However, the caloric restriction group significantly improved their HEI component score for added sugar compared to the liraglutide group ( p = 0.002) when adjusted for baseline intake. Despite the treatment group, participants failed to meet several of the same nutrition recommendations, including those for fruit, vegetable and dairy intake.

Conclusions

Overall diet quality was poor across all groups. However, the caloric restriction group significantly reduced its added sugar intake, highlighting a potential benefit nutrition counselling may have for AOM users. Future research is needed to examine the long‐term impact of AOM use on dietary intake, with and without nutrition guidance, to better inform clinical recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutidePrediabetic StateObesityGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsFeeding BehaviorHumansFemaleMiddle AgedMaleAdultCaloric RestrictionEnergy IntakeDipeptidyl-Peptidase IV InhibitorsDiet

Stichwörter der Autor:innen

antiobesity drugclinical trialdietary interventionliraglutideobesity therapyweight management

Substanzen

LiraglutideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Veteran Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.

ORCID-Profile: Kelli M Richardson, Heidi J Silver

Förderung

  • NCATS NIH HHS
  • American Heart Association
  • National Center for Advancing Translational Sciences

Zitieren

APA

Richardson, K. M., Schembre, S. M., Jospe, M. R., Widmer, A., & Silver, H. J. (2025). The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 27(7), 3725-3735. https://doi.org/10.1111/dom.16395

Vancouver

Richardson KM, Schembre SM, Jospe MR, Widmer A, Silver HJ. The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism. 2025;27(7):3725-3735. doi:10.1111/dom.16395

BibTeX
@article{Richardson2025,
  author = {Richardson, Kelli M and Schembre, Susan M and Jospe, Michelle R and Widmer, Annaliese and Silver, Heidi J},
  title = {The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3725--3735},
  doi = {10.1111/dom.16395}
}
Kostenlos starten →